TY - JOUR
AU - NOUJAIM, A. A.
AB - A novel method for generating monoclonal antibodies against synthetic tumour-associated glycoconjugates has been developed. One of these monoclonal antibodies, designated 170H.82, was derived against the TF antigen and has been shown in vitro to have a wide range of reactivity with adenocarcinoma. This antibody has been labelled with
TI - MAb 170H.82 an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with  99 m 111
JF - Nuclear Medicine Communications
DA - 1992-01-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/mab-170h-period-82-an-evaluation-of-a-novel-panadenocarcinoma-V6bUZc6B0c
SP - 11–19-11&ndash
EP - ndash;19-11–19
VL - 13
IS - 1
DP - DeepDyve
ER -